Biovie (BIVI) Change in Accured Expenses (2014 - 2023)
Biovie (BIVI) posted Change in Accured Expenses of -$48385.0 for Q3 2023, up 66.67% sequentially from -$145157.0 in Q2 2023, and up 94.44% YoY from -$24884.9 in Q3 2022.
Biovie (BIVI) Change in Accured Expenses (2014 - 2023) Analysis & Trends
Biovie has reported Change in Accured Expenses for 8 years, with the latest figure at -$48385.0 in Q3 2023.
- Quarterly Change in Accured Expenses rose 94.44% year-over-year to -$48385.0 in Q3 2023, while the trailing twelve-month figure through Jun 2024 was -$48385.0 (up 96.29% YoY) and the FY2024 annual result came in at -$48385.0, up 96.29% from the prior year.
- Change in Accured Expenses rose to -$48385.0 in Q3 2023 per BIVI's latest filing, from -$145157.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $1.1 million in Q3 2021 and troughed at -$869456.0 in Q3 2022.
- A 3-year average of $0.0 and a median of -$145156.0 in 2021 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses slumped 181.68% in 2022, then jumped 94.44% in 2023.
- Over 3 years, Change in Accured Expenses stood at -$145156.0 in 2021, then changed by 0.0% to -$145156.0 in 2022, then jumped by 66.67% to -$48385.0 in 2023.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$48385.0, -$145157.0, and -$145156.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -48,385.00 |
| Sep 30, 2023 | -48,385.00 |
| Jun 30, 2023 | -145,157.00 |
| Jun 30, 2023 | -145,157.00 |
| Mar 31, 2023 | -145,156.00 |
| Mar 31, 2023 | -145,156.00 |
| Dec 31, 2022 | -145,156.00 |
| Dec 31, 2022 | -145,156.00 |
| Sep 30, 2022 | -869,456.00 |
| Sep 30, 2022 | -869,456.00 |
| Jun 30, 2022 | 579,143.00 |
| Jun 30, 2022 | 579,143.00 |
| Mar 31, 2022 | -145,156.00 |
| Mar 31, 2022 | -145,156.00 |
| Dec 31, 2021 | -145,156.00 |
| Dec 31, 2021 | -145,156.00 |
| Sep 30, 2021 | 1.06 Mn |
| Sep 30, 2021 | 1.06 Mn |
| Jun 30, 2018 | 41,667.00 |
| Jun 30, 2018 | 41,667.00 |